CD4 + CD25 + regulatory T cells (Treg) are essential negative regulators of immune responses. Here, we examined the signaling properties of human Treg, using CD4 + CD25 + Treg and CD4 + CD25control (Tcont) cell lines generated from cord blood.
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ABSTRACT
CD4 + CD25 + regulatory T cells (Treg) are essential negative regulators of immune responses. Here, we examined the signaling properties of human Treg, using CD4 + CD25 + Treg and CD4 + CD25control (Tcont) cell lines generated from cord blood.
Treg cell lines were markedly hyporesponsive to stimulation with dendritic cells and with anti-CD3/CD28 coated beads. Hyporesponsiveness was reversed by exogenous IL-2.
TCR/CD3-plus-CD28 mediated activation of Rap1 and Akt was retained in Treg but activation of Ras, MEK1/2 and Erk1/2 was impaired. Treg were blocked from cell cycle progression due to decrease of cyclin E and cyclin A and increase of p27 kip1 . IL-2 induced sustained increase of cyclin E and cyclin A and prevented upregulation of p27 kip1 . Treg had high susceptibility to apoptosis that was reversed by IL-2, which correlated with activation of Erk1/2, upregulation of Bcl-x L and phosphorylation of Bad at Ser 112 . Thus, Treg share biochemical characteristics of anergy, including abortive activation of Ras-MEK-Erk, increased activation of Rap1, and increased expression of p27 kip1 . In addition, our results indicate that TCR/CD3-plus-CD28-mediated and IL-2 receptor-mediated signals converge at the level of MEK-Erk kinases to regulate Treg survival and expansion and suggest that manipulation of the MEK-Erk axis may represent a novel strategy for Treg expansion for immunotherapy.
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INTRODUCTION
CD4 + CD25 + Treg are a naturally occurring subpopulation of T cells with immunosuppressive function. Treg prevent autoimmunity but can also inhibit rejection of transplants, prevent the induction of anti-tumor responses and regulate the immune response to infectious diseases 1 . These natural properties make Treg attractive tools for novel immunotherapeutic approaches. Extensive studies using mouse experimental models have provided compelling evidence that Treg can induce transplantation tolerance, prevent GVHD, and control allergy and autoimmunity [2] [3] [4] .
A practical problem that prevents the clinical applicability of these experimental approaches is the difficulty to isolate sufficient numbers of Treg cells from human blood.
Development and expansion of Treg cells in vivo require both TCR/CD3-plus-CD28mediated and IL-2 receptor-mediated signals 5, 6 . Using these natural stimulatory requirements of Treg, recent studies achieved in vitro generation of human Treg cell lines from cord blood CD4 + CD25 + Treg by culture with anti-CD3 plus anti-CD28 mAbs coated beads and IL-2 7 . These cell lines exhibit enhanced suppressor function compared to freshly isolated CD4 + CD25 + Treg cells and potentially provide an ideal tool for immunotherapy. Despite progress in the in vitro generation of CD4 + CD25 + Treg cell lines, their replicative capacity is impaired. Thus, an approach to efficiently expand these in vitro generated Treg for in vivo immunotherapy is desirable. Identification of the molecular pathways that regulate cell cycle progression and viability may provide novel molecular targets for intervention in order to achieve large-scale expansion of Treg in vitro, and obtain cell numbers sufficient for immunotherapy.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Mitogen-activated protein kinase-extracellular signal-regulated kinase (MEK-Erk) and Phosphatidylinositol-3-kinase (PI3K) and Akt/protein kinase B (hereafter referred to as Akt) play a critical role in T cell survival, expansion and differentiation 8, 9 . These pathways can be activated via TCR/CD3, CD28 costimulation as well as via the IL-2 receptor 10,11 . As mentioned above, both TCR-plus-CD28 and IL-2 receptor mediated signals are required for development and expansion of Treg cells in mice 5, 6 . For these reasons we investigated whether these signaling pathways are involved in TCR/CD3plus-CD28-mediated stimulation and in IL-2 receptor mediated stimulation of human Treg cells.
We used Treg cell lines and paired control (Tcont) cell lines generated respectively from CD4 + CD25 + and CD4 + CD25cord blood cells 7 . These cell lines provide a useful tool to examine the signaling properties of Treg, studies that require high cell numbers that cannot be obtained using primary, naturally occurring human Treg cells. Our studies showed that TCR/CD3-plus-CD28-mediated activation of Rap1 and Akt was retained in Treg, but activation of Ras, MEK1/2 and Erk1/2 was defective. Treg entered the cell cycle but progression through the cell cycle was blocked due to rapid downregulation of cyclin E and cyclin A, and increase of p27 kip1 . Addition of exogenous IL-2 prevented upregulation of p27 kip1 and induced a sustained increase of cyclin E and cyclin A. Treg were prone to apoptosis; exogenous IL-2 induced activation of Erk1/2 at levels equivalent to those of Tcont, expression of Bcl-x L , phosphorylation of Bad at Ser 112 and prevented apoptosis.
Thus, Treg share many biochemical characteristics of anergy, including defective activation of Ras-MEK-Erk pathway, enhanced activation of Rap1, increased expression 
MATERIALS AND METHODS
Generation and culture of Treg and Tcont cell lines.
CD4 + CD25 + and CD4 + CD25cells were isolated from umbilical cord blood mononuclear cells (CBMC) (Saint Louis Blood Bank, St. Louis, MO) and Treg and control (Tcont) cell lines were generated as described previously 7 . Briefly CD25 + cells were positively selected from CD34-negative CBMC by CD25+ magnetic beads (MiltenyiBiotec, Auburn, CA). CD4+CD25-cells were positively selected from exhaustively CD25 depleted CD34-negative CBMC. Cells were cultured once with anti-CD3 and anti-CD28 coated dynal beads (U. Pennsylvania) at a 3 beads/1 cell ratio.
Media was RPMI 1640 plus 10% FCS supplemented with glutamax, penicillin, streptomycin (Gibco/Invitrogen, Carlsbad,CA). Cells were split as needed and fed media containing 50 U IL-2 (Chiron, Emeryville, CA) every 3-4 days. Cell lines became quiescent after 3 weeks, and were used for functional and molecular experiments at 3-4 weeks. All CD25+ derived lines were shown to be potently suppressive by allogeneic DC MLR assay 6 . Prior to use in stimulation experiments, cell lines were dynal bead depleted and rested overnight in culture medium. Cell lines were subsequently cultured as indicated to examine proliferation, IL-2 production, cell cycle progression and susceptibility to apoptosis.
Proliferation and cytokine analysis.
Cells were cultured at a concentration of 50,000 cells/well in 96 well flatbottom plates (Costar) with anti-CD3 and anti-CD28-coated dynalbeads (U. Pennsylvania). 
Cell activation, Western blotting and GST-pull down assay.
For activation experiments Treg and Tcont cell lines were rapidly mixed with anti-CD3 and anti-CD28-coated dynalbeads and incubated at 37 0 C for the indicated time intervals. Cells were lysed 12 and equal amounts of protein were analyzed by SDS-PAGE and immunoblot. Blots were stripped and reprobed as indicated. Antibodies specific for phosphorylated Akt, phosphorylated MEK1/2, Erk1/2 and phosphorylated Bad(ser 112 ) were from Cell Signaling Technologies (Beverly, MA). Antibodies for phosphorylated Erk1/2, phosphorylated Bad(ser 136 ), cyclin D2, cyclin E, cyclin A, cdk2, cdk4 and p27 were from Santa Cruz Biotechnology (Santa Cruz, CA). Rb-specific antibody was from Pharmingen (CA). Antibody for Bcl-2 was from DakoCytomation (Denmark), Bcl-x L 8 was from Biosource International Inc. (Camarillo, CA). To detect Rap1GTP and RasGTP, cell lysates were incubated with GST-RalGDS-RBD and GST-Raf1-RBD respectively, coupled with Glutathione Sepharose beads 13 . Complexes were analyzed by SDS-PAGE and blotted with anti-Rap1 (Santa Cruz Biotechnology, CA) or anti-Ras (Oncogene, CA) antibodies.
Assessment of cell viability.
Analysis of viability was performed using an Annexin V-based apoptosis detection kit (R&D systems).
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RESULTS
Cord blood Treg cell lines exhibit impaired proliferation and IL-2 production.
First we examined the functional properties of Treg and Tcont cells lines. After stimulation by anti-CD3-plus-anti-CD28 coated beads, assessment of proliferation was determined by 3 H-thymidine incorporation. A significant degree of 3 H-thymidine incorporation was detected in both Treg and Tcont cell lines at 24 hours of culture ( Figure 1A ). However, in subsequent days, only Tcont retained their ability for DNA synthesis, whereas proliferation of Treg cells rapidly declined ( Figure 1A ). Assessment of IL-2 production revealed that, similarly to their proliferation capacity, Tcont produced significant levels of IL-2 at 24 hours of culture ( Figure 1B ). High levels of IL-2 were detectable in the culture supernatants up to 5 days of culture. In contrast, low levels of IL-2 were detected only on the first day of Treg cell culture and rapidly declined thereafter ( Figure 1B ). This pattern of proliferation and IL-2 production of Treg and Tcont cell lines from cord blood was similar to that observed when Treg and Tcont cell lines generated from peripheral blood were analyzed 14 , and was obtained with multiple lines generate from various individuals (data not shown). Importantly, addition of IL-2 in Treg stimulated with anti-CD3-plus-anti-CD28 coated beads, resulted in augmented and sustained proliferation ( Figure 1C ).
To determine whether Treg cell lines did not respond to TCR/CD3 plus CD28 Interestingly, when treated with pharmacologic stimulators phorbol ester and the calcium ionophore ionomycin (PMA+IM), that overcome the TCR proximal signaling events, Treg were capable of proliferating and producing IL-2 (data not shown). These results indicate that Treg do not have an irreversible intrinsic inability to produce IL-2 and suggest that altered TCR/CD3-plus-CD28 mediated signaling events may result in the inability of Treg to produce IL-2 when stimulated via their antigen receptor in the presence of costimulation. These functional properties of Treg highly resemble those of anergic CD4 + T cells that are incapable of responding to antigen-specific stimulation via their TCR but can respond to stimuli that bypass TCR-proximal signaling 15 .
Activation of Ras-MEK-Erk is impaired but activation of PI3K-Akt and Rap1 is retained in human Treg.
PI3K regulates IL-2 transcription via its downstream target Akt and activated Akt can substitute for CD28 costimulation for the induction of IL-2 gene transcription 16 .
These observations suggest that defective TCR/CD3-plus-CD28-mediated production of IL-2 in Treg cells may be related to an impaired ability of these cells to activate Akt.
Such hypothesis was also supported by our previous observation that in primary human T lymphocytes the PI3K-Akt pathway is required for IL-2 production and cell cycle progression 11 . Interestingly, activation of Akt was detectable at comparable levels in TCR/CD3-plus-CD28-stimulated Treg and Tcont cell lines (Figure 2A The above results suggested that signals controlling cell cycle progression were differentially activated in Treg and Tcont cells. Analysis of the cell cycle regulatory molecules showed that both cell types were capable of expressing cyclin D2, indicating that they could enter G1 phase. However, a significant difference was detected in the expression pattern of cyclin E, which is induced at the late G1 phase at the stage of transition through the G1 restriction point. Although in Treg cells induction of cyclin E was detected at 24 and 48 hours, expression of cyclin E was not sustained at 72 hours.
Similarly, cyclin A was upregulated at 24 and furthermore at 48 hours but was significantly decreased at 72 hours of culture ( Figure 3A, lanes 1-4) . In contrast in Tcont cells, cyclin E and cyclin A were upregulated at 24 hours and remained at high levels at 72 hours of culture ( Figure 3, lanes 5-8) .
Conversely, Tcont cells had a significant decrease of p27 kip1 cdk inhibitor after culture ( Figure 3 , lane 5-8), whereas Treg cells not only did not exhibit decrease of p27 kip1 , but they had a gradual increase of p27 kip1 that exceeded the levels of background expression by 72 hours of culture ( Figure 3, lanes 1-4) . One interpretation of these results is that Treg pass through the G1 restriction point and synthesize cyclin E, enter the S phase and synthesize cyclin A, but exit S phase and return to the G1 phase of the cell cycle, where they do not express cyclin E or cyclin A, but express high levels of p27 kip1 .
Consistent with this, phosphorylation of Rb was detected at 24 and 48 of culture, but declined and returned to the unphosphorylated form at 72 hrs of culture. In contrast, in Tcont cells, which express high levels of cyclin E and cyclin A, a high degree of Rb phosphorylation was detectable at 72 hours of culture ( Figure 3B ). IL-2 is a critical factor for expansion of Treg in vitro and in vivo 5, 18, 19 . Because our Treg cell lines were incapable of sustained IL-2 secretion, we examined whether their inability to progress through the cell cycle might be reversed by addition of exogenous IL-2. Indeed, addition of IL-2 in Treg prevented upregulation of p27 kip1 and induced sustained expression of cyclin E and cyclin A at day 3 of culture ( Figure 3C, lanes 2, 3) .
In contrast, addition of IL-2 in Tcont did not alter the expression of cyclins, cdks or p27 kip1 on day 3 of culture, consistent with the hypothesis that endogenously produced IL-2 was sufficient to induce these events ( Figure 3C, lanes 5, 6) .
Treg cells become susceptible to activation-induced apoptosis and are rescued by
IL-2.
Besides promoting cell expansion, IL-2 has been shown to have a critical role in promoting viability of Treg cells 5, 20 . For this reason, we examined whether Treg cell lines that do not produce IL-2 were susceptible to activation-induced apoptosis. As determined by Annexin V/PI staining, Treg but not Tcont cell lines became highly susceptible to apoptosis after 72 hours of culture with anti-CD3-plus-anti-CD28 coated beads ( Figure 4A ). Addition of exogenous IL-2 significantly prevented apoptosis and promoted cell viability ( Figure 4A ).
IL-2 induces activation of Erk and upregulates expression of Bcl-x L , and phosphorylation of Bad on Ser 112 in Treg cells.
Our studies showed that Treg required concomitant TCR/CD28 and IL-2 receptor mediated signals in order to proliferate. Moreover, we determined that TCR/CD28 mediated stimulation induced successful activation of the PI3K target Akt, but impaired activation of the MEK1/2 target Erk1/2. For these reasons, we investigated the role of IL-2 in activation of PI3K-Akt and MEK-Erk pathways in Treg cells. As shown in Figure   4B , prior to addition of exogenous IL-2, Treg cells had a significant degree of Akt phosphorylation that was comparable to that observed in Tcont cells ( Figure 4B, lanes 1   and 3) . Addition of IL-2 slightly augmented activation of Akt in Treg cells ( Figure 4B,   lanes 1, 2) . IL-2 induced significant activation Erk1/2 in Treg ( Figure 4B, lanes 1, 2) , whereas is had no effect on activation of Erk1/2 in Tcont cells ( Figure 4B, lanes 3, 4) .
These results indicate that TCR/CD3-plus-CD28 mediated signals in Treg cells were sufficient to induce activation of Akt to levels comparable to those in Tcont cells, and further, that Akt phosphorylation may be independent of IL-2 signals. However, optimal activation of Erk1/2 is IL-2 dependent, as high level activation of Erk1/2 was only achieved in Tcont cells that produced large amounts of endogenous IL-2. In contrast, exogenous IL-2 was required to induce this level of Erk1/2 activation in Treg cells.
In T lymphocytes IL-2 also promotes viability by regulating expression of Bcl-2 family members 21 . Therefore, an obvious question was whether IL-2 regulated expression of Bcl-2 family members in Treg cells. Among the 20 members of the Bcl-2 family, Bcl-2 and Bcl-x L have the most critical role in promoting viability in T lymphocytes 22 . Bcl-2 was expressed at comparable levels in TCR/CD3-plus-CD28
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From cultured Treg and Tcont and addition of IL-2 did not affect its expression ( Figure 4C ). In contrast, Bcl-x L was selectively upregulated by IL-2 in Treg ( Figure 4C, lanes 1, 2) , whereas in Tcont cells it was expressed at high levels prior and after addition of IL-2 ( Figure 4C, lanes 3, 4) .
Bad is a BH3-only proapoptotic member of the Bcl-2 family that couples death signals to mitochondria and promotes apoptosis by quelling the protective action of Bcl-2 and/or Bcl-x L 23 . Phosphorylation of Bad inactivates its proapoptotic function in a mechanism involving binding to 14-3-3 scaffold proteins that results in sequestering of Figure 3C, lanes 2, 3) . The observation that IL-2 did not downregulate p27 kip1 in human Treg is consistent with a previous report in which the effects of IL-2 in mouse Treg were analyzed 29 Our present results are in agreement with earlier observations, which have shown that mouse CD4 + CD25 + Treg were incapable of activating Akt after IL-2 receptor ligation but were capable of activating this substrate following TCR/CD3-plus-CD28
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As shown here, TCR/CD3-plus-CD28 signals led to activation of Akt but not Erk1/2, and did not allow for protection from apoptosis and cell cycle progression of Treg cells. The addition of IL-2 did not have any effect on Akt activation, but induced activation of IL-2/IL-2 receptor signaling prevents Treg from undergoing activation induced cell death. Treg and Tcont T cell lines were rested or stimulated with anti-CD3 and anti-CD28 coated dynalbeads for three days, or with anti-CD3 and anti-CD28 coated dynalbeads and IL-2 as described in Figure 3 For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
